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Abstract
Background: Suicidal behaviour is a complex phenomenon with a multitude of risk factors. Brain-derived
neurotrophic factor (BDNF), a protein crucial to nervous system function, may be involved in suicide risk. The
objective of this systematic review is to evaluate and summarize the literature examining the relationship between
BDNF levels and suicidal behaviour.
Methods: A predefined search strategy was used to search MEDLINE, EMBASE, PsychINFO, and CINAHL from
inception to December 2015. Studies were included if they investigated the association between BDNF levels and
suicidal behaviours (including completed suicide, attempted suicide, or suicidal ideation) by comparing BDNF levels
in groups with and without suicidal behaviour. Only the following observational studies were included: case-control
and cohort studies. Both clinical- and community-based samples were included. Screening, data extraction, and risk
of bias assessment were conducted in duplicate.
Results: Six-hundred thirty-one articles were screened, and 14 were included in the review. Three studies that assessed
serum BDNF levels in individuals with suicide attempts and controls were combined in a meta-analysis that showed no
significant association between serum BDNF and suicide attempts. The remaining 11 studies were not eligible for the
meta-analysis and provided inconsistent findings regarding associations between BDNF and suicidal behaviour.
Conclusions: The findings of the meta-analysis indicate that there is no significant association between serum BDNF
and attempted suicide. The qualitative review of the literature did not provide consistent support for an association
between BDNF levels and suicidal behaviour. The evidence has significant methodological limitations.
Systematic review registration: PROSPERO CRD42015015871
Keywords: Suicide, Attempted suicide, Suicidal ideation, Brain-derived neurotrophic factor, Systematic review,
Meta-analysis
Background
Suicide is a growing public health concern. Worldwide,
over 800,000 people die by suicide every year, and the
numbers are increasing [1]. Suicide affects not only the
individual but the family, community, and society in
which it occurs. Non-fatal suicidal behaviours, which
refer to a complex set of thoughts, plans, and acts
intended to end one’s life, are significant risk factors for
completed suicide and occur 10–20 times more often
than completed suicide [1, 2].
A multitude of factors are thought to contribute to the
risk of suicidal behaviour, including internal (biological
and psychological) and external (social and environmen-
tal) factors. Examples of internal risk factors include
psychiatric disorders, substance-use disorders, chronic ill-
ness, and demographic variables (such as older age and fe-
male sex) [3]. External risk factors can include unmarried
status, unemployment, and a lack of social support [2, 3].
Most suicidal behaviour occurs in the context of a psychi-
atric disorder (90 % of attempted or completed suicides),
but most individuals with psychiatric disorders never
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attempt suicide [3, 4]. In addition, many cases of suicide
cannot be explained by the conventional risk factors that
have been proposed by research and clinical observations.
Consequently, there is a need to identify predictors of sui-
cidal behaviour beyond the known risk factors [2].
Recent research has focused on biological markers of
suicide risk, such as genetic variants and circulating pro-
teins [5]. One such protein is brain-derived neurotrophic
factor (BDNF), a member of the neurotrophin family of
proteins. BDNF is found in the brain and throughout
the body in the bloodstream [6]. It is crucial to a number
of neural processes, such as neurogenesis, neuroplasti-
city, and neurotransmission [6, 7].
Altered BDNF levels may play a role in the pathogen-
esis of suicidal behaviour by resulting in long-term
changes in the brain that can lead to neuropsychological
deficits. A number of studies have shown that changes
in brain structure and function may be associated with
depression, stress, and suicidal behaviour. These changes
include reductions in neuron cell number, density, and
size, as well as decreased cortical thickness and changes
in synaptic circuitry [8–11]. Other studies demonstrate
cognitive deficits in stress and depression [12]. This evi-
dence supports a new hypothesis that links the patho-
genesis of suicidal behaviour and depression to altered
neural plasticity, which impairs the brain’s ability to re-
spond appropriately to environmental stimuli [13, 14]. It
is hypothesized that pathological changes in BDNF
levels are distally responsible for these neuropsycho-
logical deficits associated with depression, stress, and
suicide [6].
It is also possible that short-term changes in BDNF
levels may be involved in suicidal behaviour pathogen-
esis. There is evidence that BDNF levels can undergo
short-term variations in response to external stimuli.
Serum BDNF levels have been shown to increase follow-
ing a 3-month reduced-calorie diet [15] and endurance
training [16]. Antidepressant treatment in depressed in-
dividuals normalizes low levels of BDNF [17]. Alcohol
and tobacco use have also been linked to altered levels
of BDNF; excessive drinkers tend to have lower serum
BDNF levels, and current smokers tend to have
higher serum BDNF levels [18]. These and other vari-
ables may explain variations in BDNF level between
and within individuals over time. These factors may
also be related to risk of suicidal behaviour and could
explain how BDNF might be related to suicidal be-
haviour in a proximal manner. However, there is no
conclusive evidence linking short-term changes in
BDNF to suicidal behaviour.
While BDNF is primarily produced in the central ner-
vous system, it also expressed in peripheral tissue in
smooth muscle cells, endothelial cells, endocrine cells,
and immune cells [18]. It has been shown to cross the
blood-brain barrier, and blood levels of BDNF are re-
flective of brain levels [19]. Brain levels of BDNF can be
measured in postmortem brain tissue, and circulating
levels can be measured in the blood (serum or plasma)
and cerebrospinal fluid (CSF) of living individuals.
Altered central and peripheral BDNF levels have been
implicated in both depression [20–22] and stress [23–26],
both of which are risk factors for suicidal behaviour [6].
Furthermore, altered BDNF levels have been linked to sui-
cidal behaviour in postmortem brain studies [27, 28].
Clinical studies have shown reduced peripheral BDNF
levels in both the serum and plasma of suicidal individuals
[29–31]. While this is a growing area of research, the rela-
tionship between BDNF levels and suicidal behaviour re-
mains unclear, as relatively few studies have explored this
relationship. In addition, since some of these studies have
examined recent suicidal behaviour while others examined
lifetime suicidal behaviour, it is uncertain whether BDNF
is related to suicide in a distal or proximal manner. To
date, there has not been a systematic review undertaken
to summarize the literature.
This paper aims to systematically evaluate and
summarize the existing literature relating BDNF levels
(including central and peripheral levels) to suicidal
behaviour (including completed suicide, attempted
suicide, and suicidal ideation) in adult populations.
Based on our current understanding of BDNF and its
role in brain structure and function, it is expected
that low BDNF levels will be associated with suicidal




The protocol for this systematic review was published pre-
viously [32]. This systematic review follows the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines as well as the Meta-analysis of Obser-
vational Studies in Epidemiology (MOOSE) guidelines (see
Additional file 1 for PRISMA checklist). An a priori-defined
search strategy was developed with the help of an experi-
enced health sciences librarian (LB) and was used to search
the following databases from inception until December
2015: PubMed/MEDLINE, PsychINFO, EMBASE, and
CINAHL. The search strategy can be found in the pub-
lished protocol. One amendment was made to the original
search strategy. Because many cases of suicidal behaviour
involve overdose of substances, two search terms (“self poi-
son” and “overdose”) were added to capture studies of those
behaviours. An example of the search strategy for MED-
LINE is presented in Table 1. The grey literature was
searched for previously published theses using the Pro-
Quest Dissertations and Theses A&I database. The refer-
ence lists of included articles were scanned manually.
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Inclusion and exclusion criteria
This review included observational studies that investi-
gated associations between levels of BDNF (central or per-
ipheral, including postmortem brain tissue, cerebral spinal
fluid, and blood) and suicidal behaviours (including com-
pleted suicide, attempted suicide, and suicidal ideation) in
adult populations (aged 18 and older). Studies of both
clinical and community-based samples were included. No
demographic limitations were applied apart from age.
Screening and data extraction
Two raters (RE and SP) screened the articles identified by
the literature search. Articles were screened first by title,
then by abstract for full-text review. Studies that met the
inclusion criteria upon full-text review were identified for
data extraction. For articles that were excluded, reasons
for exclusion were documented (see Fig. 1). Discrepancies
at any point in the screening process were resolved by dis-
cussion, and in cases of disagreement, a third rater (ZS)
was consulted. The Kappa statistic was used to calculate
inter-rater agreement [33].
Two independent raters (RE and SP) performed the
data extraction in duplicate. A pre-established, pilot-
tested data extraction form was used. The following in-
formation was obtained from each study: study informa-
tion (title, author, publication year, journal name,
location of study), study setting and design, description
of sample and comparison groups, sample size, defin-
ition and measurement of suicidal behaviour, type of
BDNF sample, statistical methods, mean BDNF levels
and standard deviations, and limitations. Four authors
were contacted for further information, and one
responded with numerical data not presented in the art-
icle. One article was published in Mandarin [34], so a
fluent Mandarin speaker assisted with the determination
of its eligibility and data extraction. Risk of bias in in-
cluded studies was assessed in duplicate using an
adapted version of the Newcastle-Ottawa Scale, which
assesses for risk of selection bias, performance bias, de-
tection bias, and information bias [35].
Results
Search results
The database search retrieved 631 records. After the re-
moval of duplicates, 488 titles were screened, and 438
records were excluded. An additional 30 were excluded
upon the review of the abstracts. Twenty full-text arti-
cles were assessed for eligibility. Of these, 14 were in-
cluded in this review (see Fig. 1 for PRISMA flow
diagram). Inter-rater agreement for the title, abstract,
and full-text screening was 0.59, 0.71, and 0.91, respect-
ively, corresponding to fair, good, and excellent agree-
ment [36].
Study characteristics
The characteristics of the included studies are summa-
rized in Table 2. Twelve of the included articles were
case-control studies, and two were cross-sectional stud-
ies. Four of the studies were postmortem studies that
measured BDNF in brain tissue samples from individuals
who had died by suicide. The remaining nine studies
were clinical studies, eight of which investigated blood
levels of BDNF (serum or plasma) in participants who
attempted suicide, and one of which investigated cere-
brospinal fluid (CSF) levels of BDNF in individuals who
experienced suicidal ideation.
Risk of bias assessment
The modified version of the Newcastle-Ottawa Scale con-
tains seven questions that fall under four domains:
methods for selecting study participants (selection bias),
methods to control for confounding (performance bias),
statistical methods (detection bias), and methods of expos-
ure and outcome assessment (information bias). Assessing
the included studies using the modified Newcastle-Ottawa
Scale revealed a number of common sources of risk of
bias. Nearly all of the studies (12/14) had samples sizes
that were small, likely resulting in insufficient power to
detect meaningful differences in mean BDNF level be-
tween groups. Most of the studies (10/14) compared
groups of between 20 and 30 participants, though some
groups were as small as 10 participants. Another signifi-
cant source of high risk of bias was the lack of adjustment
for confounding variables. While some studies matched
participants on age and/or sex in an attempt to reduce
confounding, only four of the studies adjusted for any var-
iables in their analyses. Finally, twelve of the fourteen
studies used statistical methods that are inappropriate for
observational studies. Univariate analyses were used to
compare mean BDNF levels between groups. Only two
studies [37, 38] performed a regression analysis to investi-
gate the relationship between BDNF levels and suicidal
behaviour (see Additional file 2 for a table displaying the
scores from the risk of bias assessment).
Table 1 Medline Search Strategy
Database Search Strategy
MEDLINE (n=124) 1. exp Suicide/
2. suicid*.mp.
3. exp Self-Injurious Behavior/
4. (self harm* or self inflict* or self injur* or self
wound* or self mutilat* or self poison* or
overdose).mp.
5. automutilat*.mp
6. 1 or 2 or 3 or 4 or 5
7. brain derived neurotrophic factor.mp. or
Brain-Derived Neurotrophic Factor/
8. bdnf.mp
9. 7 or 8
10. 6 and 9
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Postmortem brain studies of completed suicide
Four of the included studies examined protein levels of
BDNF in the brains of postmortem subjects [27, 28, 39, 40]
(see Table 2). These studies employed a case-control design
to compare protein levels in individuals who died by sui-
cide with levels in non-suicide deaths. The studies have a
combined total of 90 cases and 88 controls. Dwivedi et al.
(2003) [27] used the Western blot technique to determine
the protein levels of BDNF in prefrontal cortex (PFC) and
hippocampal samples from 27 individuals who died by sui-
cide and 21 non-psychiatric control subjects. They found
significant differences in BDNF expression between the
groups in both brain regions, with lower levels in the indi-
viduals who died by suicide. The authors assert that these
differences were unrelated to psychiatric diagnosis or other
measured variables (postmortem interval, brain pH, age,
and sex). In a similar study, Karege et al. (2005) [28]
compared BDNF levels in the ventral prefrontal cortex,
Fig. 2 Serum BDNF in attempted suicide. Legend: Forest plot representing the differences in serum BDNF level between individuals with suicide
attempts and psychiatric controls
Fig. 1 PRISMA flow diagram. Studies selected for inclusion with number of studies included after each stage of the screening process
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Table 2 Study Characteristics






































Suicide + MDD: 0.94 (0.22)




Suicide + MDD: 1.04 (0.20)


















Drug-free MDD: 17.7 (2.9)
Drug-free others: 16.8 (3.1)
Drug-treated MDD: 23.3 (2.2)
Drug-free controls: 24.5 (3.6)
PFC
Drug-free MDD: 13.8 (2.6)
Drug-free others: 12.7 (2.6)
Drug-treated MDD: 17.9 (2.9)
Drug-free controls: 17.5 (3.0)
Entorhinal cortex
Drug-free MDD: 14.1 (2.1)
Drug-free others: 13.4 (2.4)
Drug-treated MDD: 12.9 (2.3)


















Brain – BLA, CeA
(optical density)
BLA
Depressed suicide: 1.19 (0.80)
Depressed non-suicide: 1.67 (1.42)
Control: 1.08 (0.34)
CeA
Depressed suicide: 0.95 (0.20)



















and SSI score: r = 0.62,








































MDD patients vs. PD
































Suicidal schizophrenic: 14.60 (7.02)


















Suicidal depressed: 57.3 (9.2)
Non-suicidal depressed: 76.0 (25.7)














Suicidal MDD: 21.93 (24.71)






History of suicide attempts (12)
































Suicidal depressed: 430.5 (397.0)













Suicidal depressed: 386.61 (362.39)













Suicide attempt Plasma d
(pg/ml)
Suicidal depressed: 713.04 (236.56)
Non-suicidal depressed: 693.98 (347.84)
Control: 709.05 (172.12)
0.971 None
aMean BDNF values estimated from inspection of graph
b3 diagnosis groups: Recurrent depressive disorder, personality disorder, adjustment disorder
cMedians and interquartile ranges presented instead of means and SD
dBDNF was measured in 3 types of sample: platelet-rich plasma, platelet-poor plasma, and platelets. Results are presented here for only the platelet-poor plasma measurement
Abbreviations: BDNF brain-derived neurotrophic factor, SD standard deviation, MDD major depressive disorder, PFC prefrontal cortex, PMI postmortem interval, BLA basolateral amygdala, CeA central nucleus of the












hippocampus, and entorhinal cortex between 30 individ-
uals who died by suicide and 24 non-psychiatric controls.
The group of individuals who died by suicide was subdi-
vided into three groups by diagnosis and toxicology: un-
treated depressed, untreated other psychiatric disorder, and
drug-treated depressed. The enzyme-linked immunosorb-
ent assay (ELISA) technique was used to quantify BDNF in
the tissue samples. Significantly reduced BDNF levels were
found in both of the non-treated suicide groups compared
to the non-suicide group, in the PFC (p < 0.002) and hippo-
campus (p < 0.001), but not in the drug-treated suicide
group. No significant differences were found in the ento-
rhinal cortex of any group. The third study to look at post-
mortem hippocampal levels of BDNF was conducted by
Banerjee et al. (2013) [39]. They also employed the ELISA
method to compare BDNF levels between 21 individuals
who died by suicide and 19 non-psychiatric controls.
A significant difference was found between the
groups, with reduced BDNF levels in individuals who
died by suicide (p < 0.001). The final study to examine
brain levels of BDNF focused exclusively on the
amygdala. Maheu et al. (2013) [40] measured BDNF
levels in the basolateral amygdala (BLA) and central
amygdala (CeA) of depressed individuals (22 and 25,
respectively), and 14 healthy controls. Eleven of the
depressed subjects from which the BLA was sampled
died of suicide, and twelve of the depressed subjects
from which the CeA was sampled died of suicide. No
significant differences were found between mean
BDNF levels in individuals who died by suicide com-
pared to controls.
Cerebrospinal fluid BDNF levels and attempted suicide
Only one study examined the association between BDNF
in the CSF and suicidal behaviour. Martinez et al. [41]
compared levels of pro-inflammatory and “resiliency”
proteins (among them BDNF) between 18 depressed in-
dividuals and 25 healthy controls. While the mean
BDNF levels were not presented or compared between
suicidal and non-suicidal groups, the correlation be-
tween BDNF concentration and score on the Scale for
Suicidal Ideation (SSI) was calculated for 12 participants.
A significant positive correlation was found between
BDNF concentration and SSI score (r = 0.62, p = 0.033).
Serum BDNF levels and attempted suicide
Two of the included studies were cross-sectional studies
that investigated serum levels of BDNF in clinical sample
populations. These studies collectively assessed 241 indi-
viduals. Park et al. (2014) [42] conducted a pilot study
relating serum BDNF levels to illness severity, suicide at-
tempts, and central serotonin activity in depressed pa-
tients. The patients were stratified into subgroups based
on their history of suicide attempts; 18 had a history of
suicide attempts and 33 did not. Mean BDNF levels did
not differ significantly between the two groups (p = 0.3).
The other cross-sectional study was conducted by Pin-
heiro et al. (2012) [38] in postpartum women. Of the
190 women included, 12 had a history of suicide at-
tempts. No significant difference was found between
mean BDNF levels in this group compared to the
women with no history of suicide attempt (p = 0.6).
However, in women with postpartum affective disorder
(n = 29), suicide risk, as measured with the suicidality
section of the Mini International Neuropsychiatric Inter-
view (MINI), was significantly associated with lower
BDNF levels (p = 0.02).
The remaining four studies of serum BDNF and sui-
cidal behaviour were case-control in design. The studies
include a combined total of 148 cases and 335 controls.
Two studies [29, 34] compared individuals with suicide
attempts to both psychiatric and healthy controls.
Deveci et al. (2007) [29] recruited 10 individuals with
suicide attempts, 24 non-suicidal depressed individuals,
and 26 healthy controls. Serum BDNF levels were found
to be significantly lower in both the suicide group and
the depressed group compared to the healthy control
group (p = 0.004). However, there was no significant dif-
ference between BDNF levels in the suicide and de-
pressed groups. Liang et al. (2012) [34] conducted a
study comparing BDNF levels in depressed patients, with
and without a history of suicide attempts, and healthy
controls. The sample consisted of 31 depressed individ-
uals with suicide attempts, 34 depressed individuals
without suicide attempts, and 30 healthy controls.
Serum BDNF levels were significantly different among
the three groups, with the lowest levels in the suicide
group (p < 0.01). Among the 65 depressed individuals,
BDNF levels were negatively correlated with scores on the
Self-rating Idea of Suicide Scale (SIOSS) (p < 0.01) [34].
The final two studies of serum BDNF levels focused
on specific psychiatric disorders. Huang and Lee (2006)
[43] measured BDNF levels in a group of 126 patients
with schizophrenia, 11 of which had a history of suicide
attempts. No significant difference in mean BDNF level
was found (p = 0.841). In a study by Grah et al. (2014)
[37], associations between BDNF levels and suicidal be-
haviour were explored in patients suffering from depres-
sion, personality disorders, and adjustment disorders.
The study included 51 patients with recurrent depressive
disorder, 26 of which were suicidal; 59 patients with
personality disorders, 33 of which were suicidal, 62
patients with adjustment disorders, 37 of which were
suicidal; and 60 healthy controls. Significantly lower
BDNF levels were found in those with suicide at-
tempts in the personality disorder and adjustment
disorder groups (p = 0.003, p = 0.009, respectively), but
not in the depressed group.
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A meta-analysis was performed using the results of
three case-control studies that compared serum BDNF
levels between suicide attempters and psychiatric con-
trols [29, 34, 43] (Figure 2). These studies were selected
for inclusion in the meta-analysis based on their similar
study designs (all case-control studies), definitions of
suicidal behaviour (attempted suicide), and comparison
groups (psychiatric controls). A random-effects model
was used. The pooled estimate revealed a standardized
mean difference (SMD) of −0.32 (95 % CI −1.01 to 0.37),
which corresponds to a small effect size according to
Cohen’s criteria [44]. However, this estimate was not sig-
nificant (p = 0.36) and was associated with substantial het-
erogeneity (I2 = 73 %, p = 0.02).
Plasma BDNF levels and attempted suicide
Three case-control studies measured plasma levels of
BDNF in depressed individuals with and without a history
of suicidal behaviour [30, 31, 45]. These studies collect-
ively assessed 80 cases and 246 controls. Kim et al. (2007)
[30] compared 32 depressed patients hospitalized for re-
cent suicide attempts to 32 hospitalized non-suicidal de-
pressed patients and 30 healthy controls. They found
significantly reduced plasma BDNF levels in suicide
attempters compared to both control groups (p = 0.009,
p = 0.008, respectively). Lee et al. (2007) [31] mea-
sured plasma BDNF levels in 77 hospitalized de-
pressed patients (subdivided into 28 with a suicide
attempt and 49 without a suicide attempt) and 95
healthy controls. This study also found a significant
difference between BDNF levels in suicidal vs. non-
suicidal individuals, with lower levels in the suicidal
depressed group compared to the non-suicidal de-
pressed group. Lee and Kim (2009) [45] conducted a
study similar to Kim et al.’s [30] in which 20 hospital-
ized depressed individuals with recent suicide at-
tempts were compared to 20 hospitalized non-suicidal
depressed patients and 20 healthy controls. BDNF
was measured in platelet-rich plasma, platelet-poor
plasma, and platelets. In all three types of sample,
BDNF levels were significantly lower in depressed pa-
tients (suicidal and non-suicidal) compared to healthy
controls, but no significant differences were found be-
tween suicidal and non-suicidal groups.
Discussion
This systematic review aimed to evaluate and summarize
the existing literature on associations between BDNF
levels and suicidal behaviour. The 14 studies included in
this review describe comparisons of mean BDNF levels
between groups of individuals with and without suicidal
behaviour (see Table 2). The definitions of suicidal be-
haviour, the methods of measuring BDNF level, and the
sample populations, vary widely. The studies differ in
their findings and methodological quality, producing an
unclear picture of the relationship between BDNF levels
and suicidal behaviour.
Postmortem brain studies of completed suicide
The postmortem studies of BDNF levels and completed
suicide have examined multiple brain regions, including
the hippocampus, prefrontal cortex, entorhinal cortex,
and amygdala. Three studies [27, 28, 39] measured
BDNF protein levels in the hippocampus and all found
significant associations with completed suicide, suggest-
ing that individuals who die by suicide have lower levels
of BDNF. Two of those studies [27, 28] also measured
BDNF levels in the PFC and found significant inverse
associations with completed suicide. In the other brain
regions studied, the entorhinal cortex [28] and the
amygdala [40], no significant differences were found.
Of the four studies of brain BDNF levels in people
who died by suicide, only one, Maheu et al. [40], in-
cluded both psychiatric and non-psychiatric controls.
The other three studies compared individuals who died
by suicide to non-psychiatric controls. BDNF levels are
altered in depression and other psychiatric disorders. In
addition, most suicides occur in the context of a psychi-
atric disorder, suggesting that individuals with a psychi-
atric illness are a particularly vulnerable population for
suicidal behaviour. In order to determine the association
between BDNF and suicidal behaviour, a comparison
group should be derived from a psychiatric population,
in addition to healthy controls. Maheu et al.’s study was
the only postmortem study that did not find a significant
association between BDNF and suicide. The differences
found in the other three studies could have resulted
from altered BDNF levels associated with psychiatric dis-
orders rather than suicidal behaviour. Therefore, one
should be cautious when interpreting the results of the
other studies, as their significant findings may not repre-
sent an association between BDNF and suicide.
Another important factor to consider is the effect of
psychotropic medications on BDNF levels. Only one
study, Karege et al. [28], explored this variable. They
separated the group of people who died by suicide by
toxicology by determining the presence of therapeutic
drugs in the body. They found differences in BDNF
levels among the groups. They found a significant asso-
ciation between BDNF level and suicidal behaviour when
comparing drug-free suicide completers to controls, but
not when comparing drug-treated suicide completers to
controls. Future studies should investigate and control
for the effects of antidepressants and other medications
on BDNF levels in postmortem suicide deaths.
Postmortem studies are subject to a number of limita-
tions, making it difficult to draw sound conclusions from
them. Factors prior to death can affect the integrity of
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the brain’s morphology and biochemical content [46].
Depending on the cause and manner of death, changes
in blood oxygenation, brain perfusion, and acid-base bal-
ance can have varying effects on the brain and on the
variables of interest in postmortem studies. Different
methods of suicide can produce different effects on the
brains. Postmortem interval (PMI), the time between
death and freezing or fixing of the brain tissue, also in-
fluences the quality of the tissue. PMI can have complex
and unknown effects on the outcome measure being
studied [46]. Only two of the postmortem studies of
BDNF and suicide adjusted for confounding variables in
their analyses [28, 40]. Both Maheu et al. and Karege et
al. adjusted for PMI and age, and Maheu et al. also ad-
justed for brain pH. Future postmortem studies should
assess and control for factors that influence the integrity
of the brain tissue samples.
Bearing in mind these limitations, one can cautiously
conclude from the existing evidence that an association
may exist between brain levels of BDNF (particularly in
the hippocampus and prefrontal cortex) and completed
suicide. However, additional studies with larger samples
and psychiatric comparators are needed to confirm this
association.
Cerebrospinal fluid BDNF levels and attempted suicide
The one study of CSF levels of BDNF and suicidal behav-
iour, by Martinez et al. [41], found that increased levels of
BDNF were significantly associated with higher levels of
suicidal ideation. This finding is contradictory to the hy-
pothesis that lower levels of BDNF are associated with sui-
cidal behaviour. However, the sample size for the analysis
was very small (12 participants), and the analysis did not
adjust for confounding factors. Additional well-powered
studies are necessary to explore this association. At this
point, no conclusions can be drawn regarding the associ-
ation of CSF levels of BDNF and suicidal behaviour.
Serum BDNF levels and attempted suicide
The six studies of serum BDNF levels and suicidal be-
haviour vary widely in their findings. Of the studies that
looked at attempted suicide, three found significant as-
sociations and three did not. Two of the studies also in-
vestigated suicidal ideation and found a significant
relationship with BDNF levels.
The limitations of the studies’ methodologies could
have resulted in biased estimates and inconsistent find-
ings. The sample sizes were generally modest, with case
groups ranging from 10 to 31 participants. None of the
studies adjusted for confounding variables in their ana-
lyses, even though observational studies are inherently
prone to influences by many confounding variables. Of
the six studies of serum BDNF and suicidal behaviour,
only two performed adjusted analyses. Grah et al. [37]
adjusted for age, sex, and therapy, while Pinheiro et al.
[38] adjusted for previous psychiatric treatment and
stressful life events during pregnancy.
Another factor that could account for the inconsistent
findings among studies is the variation in time periods
between suicide attempts and BDNF measurement.
While Deveci et al.’s study included individuals who
were hospitalized for a recent suicide attempt, other
studies included individuals with a lifetime history of
suicide attempts. In studies including participants with a
lifetime history of suicide attempts, the BDNF measure-
ment could have occurred within weeks, months, or
years of the suicide attempt, and the precise time inter-
val is neither known nor accounted for in the analysis.
Because BDNF levels vary over time in response to a
number of external factors, the BDNF measurements in
these studies may not represent the levels at the time of
the suicide attempts. While it is unclear whether BDNF
levels constitute a predisposing or precipitating risk fac-
tor for suicidal behaviour, studies should take into con-
sideration the time intervals between attempt and BDNF
measurement and aim for consistency. It is likely that
associations between BDNF levels and suicidal behaviour
will vary depending on when BDNF levels are assessed.
Because only one of the six studies of BDNF level and
attempted suicide included recent cases, no conclusions
can be drawn regarding the relative strength of the asso-
ciation in recent as opposed to past suicide cases. Future
studies should aim to measure BDNF in closer proximity
to the suicide attempt in order to minimize the effects
of unmeasured confounders that may be influenced by
differences in time.
An additional point to consider is the varying methods
of sample selection among studies. While some of the
case-control studies separately recruited individuals who
had made suicide attempts and compared them to non-
suicidal controls [29, 34], other studies recruited individ-
uals from a psychiatric population and retrospectively
assessed their history of suicide attempts [37, 43]. Future
studies should aim to separately recruit individuals who
had attempted suicide and non-suicidal psychiatric con-
trols in order to attain larger samples of individuals with
suicide attempts and to increase the generalizability of
the findings beyond individuals with a specific psychi-
atric disorder.
The meta-analysis of case-control studies of serum
BDNF in individuals with suicide attempts and psychiatric
controls revealed a small effect size of −0.32. The p value
was not significant (p = 0.36). The high heterogeneity as-
sociated with this pooled estimate could be attributed to
the diversity in the sample populations. Liang et al.’s sam-
ple consisted of patients with major depression, Huang
and Lee’s sample consisted of patients with schizophrenia,
and Deveci et al.’s sample consisted of individuals with
Eisen et al. Systematic Reviews  (2015) 4:187 Page 9 of 12
suicide attempts with no major psychiatric disorder and
control participants with major depression. This meta-
analysis may be underpowered due to the small number
of studies included and the low sample sizes in each study.
Nonetheless, this is an important finding, as it suggests
that individuals who attempt suicide do not have signifi-
cantly altered serum BDNF levels compared to psychiatric
controls.
Further research is necessary to elucidate the relation-
ship between serum BDNF levels and suicidal behaviour,
and to ascertain whether the relationship depends on the
timing of measurements. Consistent definitions of suicidal
behaviour, research methodology, and adjustment for im-
portant confounding factors (such as medication use, body
mass index, and smoking status [18, 47, 48]) may help to
produce a clearer understanding of the relationship. Cur-
rently, the evidence does not provide convincing support
for an independent association between serum BDNF
levels and suicidality.
Plasma BDNF levels and attempted suicide
The three studies of plasma BDNF levels and suicidal be-
haviour present conflicting evidence of the relationship.
Two of the three studies [30, 31] found significant associa-
tions between plasma BDNF levels and attempted suicide,
while the third [45] did not. It is interesting to note that
two studies with very similar study designs [30, 45], in
which patients with depression who were hospitalized for
recent suicide attempts were compared to hospitalized
non-suicidal patients with depression and healthy con-
trols, had opposing findings. Kim et al.’s 2007 study found
significantly low BDNF levels in suicidal individuals com-
pared to both control groups, but Lee and Kim’s study in
2009 found no relationship between BDNF and suicidal
behaviour. The inconsistency in findings could be due to a
number of factors. In all three of these studies, univariate
analyses were used to compare BDNF levels among
groups. While participants were matched on some
variables (age and sex), no variables were adjusted for
in the analyses. In addition, the sample sizes of these
three studies are small; the group of individuals with
suicide attempts varied from 20 to 32 individuals. Fu-
ture studies should be conducted using larger sam-
ples, and using statistical analyses that adjust for
confounding variables such as medication use, body
mass index, and smoking status [18, 47, 48].
Another consideration is that, like in the studies of
serum BDNF levels, these studies vary in the time pe-
riods between BDNF measurement and suicide attempt.
Both Kim et al.’s and Lee and Kim’s studies included in-
dividuals hospitalized for recent suicide attempts, while
Lee’s study included individuals with a lifetime history of
suicide attempts. However, this does not explain the dif-
ferences in findings, since the inclusion of recent vs. past
suicide cases did not determine whether a significant as-
sociation was found between BDNF level and suicidal
behaviour.
Seeing that these three studies were all conducted at a
single research centre in Korea, and may not have in-
cluded independent samples, additional studies conducted
in other locations with diverse sample populations will
contribute valuably to the literature.
As of yet, the studies of plasma BDNF levels and sui-
cidal behaviour are few in number, inconsistent in their
findings, and subject to methodological limitations. No
conclusions can be drawn from the existing evidence on
the association between plasma levels of BDNF and
attempted suicide.
GRADE quality of evidence
While the protocol for this systematic review stated that
the Grading of Recommendations, Assessment, and
Evaluation (GRADE) framework would be used to report
the quality of evidence, it was deemed unnecessary to do
so. The GRADE framework provides a systematic ap-
proach to consider and report risk of bias, imprecision,
inconsistency, indirectness of study results, and publica-
tion bias. The GRADE framework is used to summarize
and evaluate the evidence according to outcome, and is
useful when the results of the studies have been com-
bined statistically. Seeing as only 3 of the 14 included
studies were pooled in a meta-analysis, it was not pos-
sible to evaluate the quality of the evidence using this
framework. Furthermore, the GRADE framework is best
suited to summaries of randomized controlled trials and
is rarely used for observational studies such as these.
Conclusions
This is the first systematic review to explore associations
between BDNF levels and suicidal behaviour. The meta-
analysis of studies examining serum BDNF levels and
attempted suicide revealed no significant association.
The qualitative review of the literature revealed that the
current evidence does not provide consistent support for
an association between BDNF and suicidal behaviour.
The findings of this systematic review are not in accord-
ance with the hypothesis that lower levels of BDNF are
linked to suicidal behaviour. It is possible than an associ-
ation exists in parts of the brain and bloodstream, but
the studies vary substantially in their methods and re-
sults, making it difficult to draw sound conclusions. The
studies are also subject to a number of methodological
limitations. As of yet, the studies conducted are few in
number and have high risk of bias. Moreover, distin-
guishing the role of BDNF in suicidal behaviour from its
role in mental illness is a key difficulty across studies. As
this is a relatively new area of research, currently the evi-
dence does not warrant using measures of BDNF in a
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clinical setting to assess suicide risk. Further studies that
are well-powered, include psychiatric comparator groups,
and adjust for important confounders will help to eluci-
date this relationship and may provide valuable informa-
tion to clinicians and researchers.
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